Temoporfin
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.152.970 |
| Chemical and physical data | |
| Formula | C44H32N4O4 |
| Molar mass | 680.74 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck[1] .[2] It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.[3]
Good results were obtained in 21 of 35 patients treated in Germany.[4]
It is photoactivated at 652 nm[5] i.e. by red light.
Patients can remain photosensitive for several weeks after treatment.[2]
Further reading
References
- ↑ Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". HNO (in German). 56 (4): 402–9. PMID 17516041. doi:10.1007/s00106-007-1573-1.
- 1 2 O'Connor, Aisling E; Gallagher, William M; Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.
- ↑ http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
- ↑ http://www.springerlink.com/content/g74w224824v8l013/
- ↑ "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.